Advances in Cancer Research

Erscheinungsjahr 2023
ISBN: 978-0-443-19280-7
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 151 mm x 229 mm, Gewicht: 660 g

Advances in Cancer Research, Volume 160, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research, with this updated edition covering PFKP: More Than Phosphofructokinase, Setting sail: maneuvering SHP2 activity and its effects in cancer, Mechanical factors driving cancer progression, Microsomal Glutathione Transferase 1 in Cancer and the Regulation of Ferroptosis, Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance, Head and Neck Cancer Treatment in the Era of Molecular Medicine, Applications of Tissue-Specific and Cancer-Selective Gene Promoters for Cancer Diagnosis and Therapy, and more.

Autoren/Hrsg.

Weitere Mitwirkende

Tew, Kenneth D.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
• Naturwissenschaften Biowissenschaften Biowissenschaften Genetik und Genomik (nichtmedizinisch)
• Naturwissenschaften Biowissenschaften Mikrobiologie
• Naturwissenschaften Biowissenschaften Zellbiologie

Inhaltsverzeichnis

1. PFKP: More Than Phosphofructokinase Haizhen Wang, Tiffany Penaloza, Amanda J. Manea, Xueliang Gao 2. Setting sail: maneuvering SHP2 activity and its effects in cancer Colin L. Welsh, Sarah Allen, and Lalima K. Madan 3. Mechanical factors driving cancer progression Jessanne Y Lichtenberg, Sydnie Tran, Priscilla Y Hwang 4. Microsomal Glutathione Transferase 1 in Cancer and the Regulation of Ferroptosis Jie Zhang, Zhi-wei Ye, Ralf Morgenstern, Danyelle M. Townsend, and Kenneth D. Tew 5. Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance Sandhik Nandi, Atanu Mondal, Aritra Ghosh, Shravanti Mukherjee and Chandrima Das 6. Head and Neck Cancer Treatment in the Era of Molecular Medicine Subramanya Pandruvada, Remi Kessler, and Ann Thai 7. Applications of Tissue-Specific and Cancer-Selective Gene Promoters for Cancer Diagnosis and Therapy Amit Kumar, Swadesh K. Das, Luni Emdad and Paul B. Fisher

Über Autor(innen)

Tew, Kenneth D.
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.